Aliases & Classifications for Motion Sickness

MalaCards integrated aliases for Motion Sickness:

Name: Motion Sickness 56 12 25 42 43 15 17 71 32
Airsickness 25 71
Carsickness 25 71
Seasickness 25 71
Travel Sickness 12
Riders' Vertigo 25



not likely mendelian, but shows familial aggregation


External Ids:

Disease Ontology 12 DOID:2951
OMIM 56 158280
ICD9CM 34 994.6
MeSH 43 D009041
NCIt 49 C34824
SNOMED-CT 67 37031009
ICD10 32 T75.3
MedGen 41 C0026603
SNOMED-CT via HPO 68 88425004
UMLS 71 C0001882 C0007297 C0026603 more

Summaries for Motion Sickness

MedlinePlus : 42 Motion sickness is a common problem in people traveling by car, train, airplanes, and especially boats. Anyone can get it, but it is more common in children, pregnant women, and people taking certain medicines. Motion sickness can start suddenly, with a queasy feeling and cold sweats. It can then lead to dizziness and nausea and vomiting. Your brain senses movement by getting signals from your inner ears, eyes, muscles, and joints. When it gets signals that do not match, you can get motion sickness. For example, if you are reading on your phone while riding a bus, your eyes are focused on something that is not moving, but your inner ear senses motion. Where you sit can make a difference. The front seat of a car, forward cars of a train, upper deck on a boat or wing seats in a plane may give you a smoother ride. Looking out into the distance - instead of trying to read or look at something in the vehicle - can also help. Centers for Disease Control and Prevention

MalaCards based summary : Motion Sickness, also known as airsickness, is related to space motion sickness and allergic hypersensitivity disease, and has symptoms including polydipsia, fatigue and fever. An important gene associated with Motion Sickness is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Ginger and Histamine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are abnormality of the nervous system and Decreased viability

Genetics Home Reference : 25 Motion sickness is a common condition characterized by a feeling of unwellness brought on by certain kinds of movement. The usual symptoms include dizziness, pale skin (pallor), and sweating, followed by nausea and vomiting. Affected individuals may also experience rapid breathing (hyperventilation), headache, restlessness, and drowsiness. These symptoms can be triggered by many kinds of motion, particularly traveling in a car, bus, train, airplane, or boat. Amusement park rides, skiing, and virtual reality environments can also induce motion sickness.

Wikipedia : 74 Motion sickness occurs due to a difference between actual and expected motion. Symptoms commonly include... more...

More information from OMIM: 158280

Related Diseases for Motion Sickness

Diseases related to Motion Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 space motion sickness 34.5 HRH1 AVP
2 allergic hypersensitivity disease 30.2 TACR1 TAC1 HRH1
3 cyclic vomiting syndrome 30.0 OPRM1 HTR3A CNR1
4 diarrhea 29.7 TAC1 POMC OPRM1 HTR3A HTR1A
5 migraine with or without aura 1 29.6 TACR1 TAC1 POMC OPRM1 HTR3A HTR1A
6 anxiety 29.4 TAC1 POMC OPRM1 HTR3A HTR1A CNR1
7 major depressive disorder 28.1 TACR1 TAC1 POMC OPRM1 HTR3A HTR1A
8 pathologic nystagmus 10.7
9 neurotrophic keratopathy 10.5 TACR1 TAC1
10 pica disease 10.4
11 causalgia 10.4 TACR1 TAC1
12 brain stem infarction 10.4 PCSK5 CMTR2
13 central nervous system origin vertigo 10.4 IRGC CMTR2
14 retinitis pigmentosa 67 10.4 TACR1 TAC1
15 serotonin syndrome 10.4 TAC1 HTR3A HTR1A
16 social phobia 10.4 TACR1 HTR3A HTR1A
17 epicondylitis 10.4 TACR1 TAC1
18 seizures, scoliosis, and macrocephaly/microcephaly syndrome 10.3
19 drug psychosis 10.3 HTR1A CNR1
20 drug-induced mental disorder 10.3 HTR1A CNR1
21 spontaneous ocular nystagmus 10.3 POMC CMTR2
22 substance-induced psychosis 10.3 HTR1A CNR1
23 glossopharyngeal neuralgia 10.3 TAC1 POMC
24 headache 10.3
25 neurodermatitis 10.3 TAC1 POMC
26 autonomic nervous system disease 10.2 TACR1 TAC1 OPRM1
27 arachnoiditis 10.2 TAC1 POMC
28 meniere disease 10.2
29 myofascial pain syndrome 10.2 TAC1 POMC
30 ataxia and polyneuropathy, adult-onset 10.2
31 hypochondriasis 10.2 POMC HTR3A HTR1A
32 hematuria, benign familial 10.2 HTR1A HRH1 FOS
33 alcohol use disorder 10.2 OPRM1 HTR3A HTR1A
34 atypical depressive disorder 10.2 POMC HTR1A
35 mental depression 10.2 POMC HTR3A HTR1A
36 chronic fatigue syndrome 10.2 POMC HTR3A HTR1A
37 anterograde amnesia 10.2 HTR1A FOS
38 migraine with aura 10.2 TAC1 OPRM1 AQP1
39 paine syndrome 10.1 TACR1 TAC1 OPRM1 HTR3A
40 tremor 10.1
41 central hypoventilation syndrome, congenital 10.1 TACR1 TAC1 HTR1A FOS
42 complex regional pain syndrome 10.1 TACR1 TAC1 POMC
43 somatoform disorder 10.1 TACR1 TAC1 OPRM1 HTR3A
44 trigeminal nerve disease 10.1 TAC1 OPRM1 CNR1
45 retrograde amnesia 10.1 POMC HTR1A FOS
46 sleep disorder 10.1 POMC HTR1A FOS
47 central pontine myelinolysis 10.1 AVP AQP1
48 sexual disorder 10.1 POMC HTR3A HTR1A ADRA2A
49 retinoblastoma 10.1
50 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.1

Graphical network of the top 20 diseases related to Motion Sickness:

Diseases related to Motion Sickness

Symptoms & Phenotypes for Motion Sickness

Human phenotypes related to Motion Sickness:

# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707

Symptoms via clinical synopsis from OMIM:

motion sickness

Clinical features from OMIM:


UMLS symptoms related to Motion Sickness:

polydipsia, fatigue, fever, edema, pruritus, nausea and vomiting, abdominal pain, chest pain, vertigo, constipation, headache, syncope, cyanosis, diarrhea, pain, nausea, chills, chronic pain, asthenia, sciatica, halitosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, coughing, vertigo/dizziness, signs and symptoms, respiratory, symptoms, dyspepsia, heartburn, gastrointestinal gas, oral manifestations, pelvic pain, vomiting alone, eye manifestations, urological manifestations, hypertriglyceridemic waist, body temperature changes, skin manifestations, renal colic, mobility limitation, prodromal symptoms, medically unexplained symptoms

GenomeRNAi Phenotypes related to Motion Sickness according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.72 FOS
2 Decreased viability GR00249-S 9.72 EFHD2 FOS HRH1
3 Decreased viability GR00381-A-1 9.72 AQP1 BLOC1S5 EFHD2 HTR1A HTR3A HTR3B
4 Decreased viability GR00381-A-3 9.72 HTR1A HTR3A
5 Decreased viability GR00386-A-1 9.72 AVP BLOC1S5 CMTR2 POMC
6 Decreased viability GR00402-S-2 9.72 AQP1 AVP EFHD2 EXT2 HTR1A HTR3A

MGI Mouse Phenotypes related to Motion Sickness:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 ADRA2A AQP1 AVP BLOC1S5 CNR1 FOS
2 homeostasis/metabolism MP:0005376 10.18 ADRA2A AQP1 AVP BLOC1S5 CNR1 FOS
3 hematopoietic system MP:0005397 10.14 AQP1 AVP BLOC1S5 EFHD2 FOS HRH1
4 mortality/aging MP:0010768 10.07 ADRA2A AQP1 AVP CMTR2 CNR1 EXT2
5 integument MP:0010771 9.97 BLOC1S5 CNR1 FOS HTR3A OPRM1 POMC
6 nervous system MP:0003631 9.93 ADRA2A AQP1 AVP CNR1 EFHD2 FOS
7 no phenotypic analysis MP:0003012 9.5 AVP BLOC1S5 CNR1 HTR1A OPRM1 PCSK5
8 renal/urinary system MP:0005367 9.23 AQP1 AVP BLOC1S5 HRH1 HTR3A PCSK5

Drugs & Therapeutics for Motion Sickness

Drugs for Motion Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Ginger Approved Phase 4
Histamine Approved, Investigational Phase 4 51-45-6 774
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Acetaminophen Approved Phase 4 103-90-2 1983
Fosaprepitant Approved Phase 4 172673-20-0 219090
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
Ondansetron Approved Phase 4 99614-02-5 4595
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Dimenhydrinate Approved Phase 4 523-87-5 441281
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
Hydroxyzine Approved Phase 4 68-88-2 3658
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Ibuprofen Approved Phase 4 15687-27-1 3672
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Glucagon Approved Phase 4 16941-32-5
Racepinephrine Approved Phase 4 329-65-7 838
29 Neurotransmitter Agents Phase 4
30 Hypnotics and Sedatives Phase 4
31 Anti-Allergic Agents Phase 4
32 Histamine Antagonists Phase 4
33 Histamine H1 Antagonists Phase 4
Histamine Phosphate Phase 4 51-74-1 65513
35 Dermatologic Agents Phase 4
36 Anesthetics, Local Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Analgesics Phase 4
39 Antipyretics Phase 4
40 neurokinin A Phase 4
Substance P Phase 4 33507-63-0 44359816
42 Narcotics Phase 4
43 Analgesics, Opioid Phase 4
44 Anti-Anxiety Agents Phase 4
45 Psychotropic Drugs Phase 4
46 Antipsychotic Agents Phase 4
protease inhibitors Phase 4
48 HIV Protease Inhibitors Phase 4
49 BB 1101 Phase 4
50 Anesthetics, General Phase 4

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Motion Sickness Medications and Vestibular Time Constant Unknown status NCT03270839 Phase 4 Bonine 25Mg Chewable Tablet;Kwells;Placebo Oral Tablet
2 Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness Completed NCT03755596 Phase 4 Z. officinale extract
3 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels Completed NCT02136420 Phase 4 Promethazine;Placebo
4 The Effect of Penehyclidine on Postoperative Nausea and Vomiting After Strabismus Surgery Completed NCT04054479 Phase 4 Penehyclidine;normal saline
5 The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting Completed NCT01897337 Phase 4 Aprepitant;placebo
6 Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting. Completed NCT02286752 Phase 4 Neostigmine;sugammadex
7 A Prospective Randomize Study: Prevention of Nausea and Vomiting in Plastic Surgery Completed NCT02382146 Phase 4 dexamethasone ondansetron;Dexamethasone dimenhidrinate
8 Prise en Charge Pharmacologique de l'anxiété et de la Douleur Chez Les Patients Qui Souffrent en Situation d'Urgence Traumatique pré-hospitalière : étude randomisée contrôlée en Double Aveugle Completed NCT01151696 Phase 4 Atarax (Hydroxyzine);Placebo
9 Intrathecal Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia With Morphine for Elective Caesarean Section: a Randomized Controlled Trial Completed NCT00921102 Phase 4 Bupivacaine;Morphine;Isotonic saline solution;Atropine
10 Efficacy of Pre-operative Aprepitant Plus Ondansetron vs Ondansetron Plus Placebo in Patients at Moderate-to-High Risk Post-operative Nausea (PONV) Undergoing Ambulatory Plastic Surgery Completed NCT00659945 Phase 4 Aprepitant plus Ondansetron;Ondansetron plus placebo
11 Prospective, Double Blind, Placebo Control, Study of Acetaminophen iv on Hospital Length of Stay in Morbidly Obese Individuals Undergoing Elective Laparoscopic Sleeve Gastrectomy Completed NCT02452320 Phase 4 intravenous acetaminophen;Placebo
12 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
13 Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting Completed NCT01474915 Phase 4 Aprepitant;Ondansetron;Promethazine;Dexamethasone
14 Opioid Free Versus Opioid Balanced Anesthesia in Middle Ear Surgery. Completed NCT03809949 Phase 4 Fentanyl Opioid anesthesia;Saline Nonopioid anesthesia
15 Effect of Adding Azithromycin to Dexamethasone in Preventing Post-operative Nausea and Vomiting in Caesarean Section Under Spinal Anesthesia With Spinal Opiate. Not yet recruiting NCT03165123 Phase 4 Oral Azithromycin tablet;Intravenous dexamethasone
16 An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers Terminated NCT02802514 Phase 4 Albiglutide 50mg;Albiglutide matching placebo;Exenatide 10microgram;Exenatide placebo (saline)
17 A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI-386 Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness Completed NCT04184115 Phase 3 DPI-386 Nasal Gel;Placebos
18 A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean Going Vessels for the Prevention and Treatment of Nausea Associated With Motion Sickness Completed NCT03986905 Phase 3 Scopolamine Nasal Gel
19 Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study Completed NCT00785135 Phase 3
20 Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy Completed NCT00880191 Phase 3 dexamethasone;gabapentin
21 Comparison of Sugammadex Versus Neostigmine in Women at High Risk of Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery: A Randomized Controlled Trial Completed NCT02666014 Phase 3 Sugammadex;Neostigmine
22 Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients. Completed NCT01733212 Phase 2, Phase 3 Ginger;Placebo Oral Tablet
23 Preoperative Dexamethasone Reduces Postoperative Pain, Nausea and Vomiting Following Mastectomy for Breast Cancer. Completed NCT01116713 Phase 3 intravenous dexamethasone;Homologated placebo.
24 A Randomized, Double-Blind, Double-Arm Trial Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery Under General Anesthesia With a Laryngeal Mask Airway (LMA) Completed NCT01219881 Phase 3 Desflurane;Sevoflurane
25 Motion Syros: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Tradipitant in the Treatment of Motion Sickness Recruiting NCT04327661 Phase 3 Tradipitant High Dose;Tradipitant Low Dose;Placebo
26 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Defender Pharmaceuticals Inc, (DPI)-386 Nasal Gel on Ocean-Going Vessels for the Prevention and Treatment of Nausea Associated With Motion Sickness Recruiting NCT03920644 Phase 3 Scopolamine Transdermal Patch [Transderm Scop];Scopolamine;Placebo Patch;Placebo Gel
27 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of DPI-386 Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness Recruiting NCT04272255 Phase 3 scopolamine HBr;Transdermal Scopolamine
28 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI-386 Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects With Open-Label Follow-Up Recruiting NCT03988530 Phase 3 Scopolamine
29 Pharmacokinetic and Efficacy Profile of Low-Dose Intranasal Scopolamine Spray for Motion Sickness Terminated NCT02155309 Phase 2, Phase 3 Scopolamine;Placebo
30 A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of the Safety, Pharmacokinetics, and Efficacy of DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness Terminated NCT04219982 Phase 2, Phase 3 DPI-386 Nasal Gel;DPI-386 Placebo Nasal Gel;Transderm Scop®
31 Evaluation of the Efficacy of Esomeprazole in Suppressing Nausea and Vomiting in Patients Undergoing Chemotherapy for Breast Cancer Terminated NCT00206440 Phase 3 esomeprazole
32 Levo Phencynonate Hydrochloridefor the Prevention of Motion Sickness (Seasickness): a Randomized, Double-blind, Placebo Controlled, Multicenter,PhaseⅡClinical Study Completed NCT02241629 Phase 2 placebo;levo phencynonate hydrochloride
33 Motion Sifnos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Completed NCT03772340 Phase 2 Tradipitant;Placebo
34 EFFICACY OF GINGER EXTRACT ON PAIN RELIEF FOR FIRST NORMAL POSTPARTUM WOMEN Completed NCT03617900 Phase 1, Phase 2 Ginger;Placebo oral capsule;Paracetamol
35 Effects of Transdermal Scopolamine on Occupational Performance Completed NCT00374478 Phase 2 Scopolamine
36 Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study of APD421 for the Prevention of Post-operative Nausea and Vomiting Completed NCT01510704 Phase 2 APD421;Placebo
37 Randomised, Double-blind, Placebo-controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-operative Nausea and Vomiting Completed NCT00895830 Phase 2 APD405;Placebo
38 Meclizine as a Potential Smoking Cessation Treatment Completed NCT01443858 Phase 2 Meclizine;Nicotine Patch;Placebo
39 Aromatherapy for Postoperative Nausea and Vomiting in Children: A Single Blind Randomized Clinical Trial Completed NCT02663154 Phase 2 Aromatherapy inhaler;Saline inhaler
40 A Multi-Center, Open-Label, 2-Arm, Randomized, Stratified, Parallel, Pilot Study to Assess Palonosetron vs. Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU) Completed NCT00967499 Phase 2 ondansetron;palonosetron
41 Clinical Trial of 3MDR to Treat PTSD With mTBI, With and Without Eye Movement (3MDR) Recruiting NCT03796936 Phase 2
42 A Randomized, Single-center, Crossover, Comparative Bioavailability and Adhesion Performance Study, Comparing Single Administrations of a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Completed NCT02839135 Phase 1 Reformulated scopolamine patch;Marketed scopolamine patch
43 A Window of Opportunity Trial With Meclizine in Hepatocellular Carcinoma Recruiting NCT03253289 Phase 1 Meclizine Oral Tablet
44 Virtual Reality Stress and Relief Project, Research on Quantification of VR Related Stress, Motion Sickness and Visual Fatigue Unknown status NCT02986555
45 A Double-blind Randomized Placebo Controlled Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness Unknown status NCT01198106 scopolamine;cinnarizine
46 Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe Unknown status NCT02911402
47 Parabolic Flight Induced Neuroplasticity Studied With Advanced Magnetic Resonance Imaging Methods Unknown status NCT02517216
48 Influence of Gravity on the Perception of Egocentric Distance (Blindpulling) Unknown status NCT02508545
49 Effects of Inverted Vision on Pointing and Grasping in Parabolic Flight Unknown status NCT02885844
50 Risk Factors for Nausea, Vomiting and Pruritus After Neuraxial Morphine for Cesarean Section Unknown status NCT03178058

Search NIH Clinical Center for Motion Sickness

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Bromodiphenhydramine hydrochloride
Chlorcyclizine hydrochloride
Diphenhydramine Citrate
Diphenhydramine Hydrochloride
Meclizine Hydrochloride
Promethazine Hydrochloride

Cochrane evidence based reviews: motion sickness

Genetic Tests for Motion Sickness

Anatomical Context for Motion Sickness

MalaCards organs/tissues related to Motion Sickness:

Brain, Eye, Testes, Skin, Breast, Heart, Liver

Publications for Motion Sickness

Articles related to Motion Sickness:

(show top 50) (show all 2511)
# Title Authors PMID Year
Motion sickness: an evolutionary hypothesis. 61 56
301659 1977
Normative Responses to Clinical Tests for Cervicogenic Dizziness: Clinical Cervical Torsion Test and Head-Neck Differentiation Test. 61 42
31584656 2020
Intranasal Scopolamine for Motion Sickness. 42 61
31666152 2019
Expanded table: some drugs for altitude illness, jet lag, and motion sickness. 61 42
31599874 2019
Full-immersion virtual reality: Adverse effects related to static balance. 61
32294492 2020
Postural responses to sinusoidal modulations of viewpoint position in a virtual environment. 61
32361912 2020
Cardiovascular testing of seasickness in healthy volunteers on life rafts. 61
32469001 2020
Incidence and risk factors associated with injuries during static line parachute training in Royal Thai Army. 61
32507108 2020
The Relationship Between Vestibular Migraine and Motion Sickness Susceptibility. 61
32501936 2020
Vestibular Function and Motion Sickness Susceptibility: Videonystagmographic Evidence From Oculomotor and Caloric Tests. 61
32320620 2020
Incidence and severity of Visually Induced motion Sickness during 3D laparoscopy In Operators who had No experience with it (VISION). 61
32489488 2020
Self-Administered Skills-Based Virtual Reality Intervention for Chronic Pain: A Randomized Controlled Pilot Study. 61
32374272 2020
Inner Ear Arginine Vasopressin-Vasopressin Receptor 2-Aquaporin 2 Signaling Pathway Is Involved in the Induction of Motion Sickness. 61
32165443 2020
VR motion sickness recognition by using EEG rhythm energy ratio based on wavelet packet transform. 61
31865095 2020
Effects of synchronised engine sound and vibration presentation on visually induced motion sickness. 61
32398641 2020
Knowing what's coming: Anticipatory audio cues can mitigate motion sickness. 61
32174356 2020
The association of intraoperative end-tidal carbon dioxide with the risk of postoperative nausea and vomiting. 61
31776779 2020
The brain-penetrating, orally bioavailable, ghrelin receptor agonist HM01 ameliorates motion-induced emesis in Suncus murinus (house musk shrew). 61
31722444 2020
Scopolamine Treatment and Adaptation to Airsickness. 61
32493552 2020
Vestibulo-Ocular Responses, Visual Field Dependence, and Motion Sickness in Aerobatic Pilots. 61
32493554 2020
Velocity storage: its multiple roles. 61
31913743 2020
Upper Extremity Rehabilitation Using Fully Immersive Virtual Reality Games With a Head Mount Display: A Feasibility Study. 61
31218794 2020
[Virtual reality exposure therapy for post-traumatic stress disorders, obsessive-compulsive disorders and anxiety disorders: Indications, added value and limitations]. 61
32151452 2020
Imbalance, motion sensitivity, anxiety and handicap in vestibular migraine and migraine only patients. 61
32178946 2020
Assessing the Autonomic and Behavioral Effects of Passive Motion in Rats using Elevator Vertical Motion and Ferris-Wheel Rotation. 61
32091010 2020
The effects of meclizine on motion sickness revisited. 61
32077140 2020
Visual Vertigo, Motion Sickness, and Disorientation in Vehicles. 61
32045940 2020
Ameliorative Effect of Hesperidin Against Motion Sickness by Modulating Histamine and Histamine H1 Receptor Expression. 61
31782104 2020
Motion Sickness Predictors in College Students and Their First Experience Sailing at Sea. 61
31980044 2020
Pseudo-Sensation of Walking Generated by Passive Whole-Body Motions in Heave and Yaw Directions. 61
31944988 2020
The Effect of Optic Flow Speed on Active Participation During Robot-Assisted Treadmill Walking in Healthy Adults. 61
31765315 2020
Psychometric evaluation of Simulator Sickness Questionnaire and its variants as a measure of cybersickness in consumer virtual environments. 61
31563798 2020
Effects of head motion on postural stability in healthy young adults with chronic motion sensitivity. 61
32257386 2020
Vestibular, locomotor, and vestibulo-autonomic research: 50 years of collaboration with Bernard Cohen. 61
31747361 2020
Revisiting the physiology of nausea and vomiting-challenging the paradigm. 61
31388745 2020
Motion sickness symptoms during jumping exercise on a short-arm centrifuge. 61
32525946 2020
Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer's Disease. 61
32056532 2020
Decreasing motion sickness by mixing different techniques. 61
31445459 2020
Effects of Immersive Virtual Reality Headset Viewing on Young Children: Visuomotor Function, Postural Stability, and Motion Sickness. 61
31377280 2020
Being watched over by a conversation robot may enhance safety in simulated driving. 61
31862032 2019
A Virtual Reality Video to Improve Information Provision and Reduce Anxiety Before Cesarean Delivery: Randomized Controlled Trial. 61
31850850 2019
Assessment of eye fatigue caused by head-mounted displays using eye-tracking. 61
31729983 2019
Cinnarizine: A Contemporary Review. 61
31750127 2019
Moving base driving simulators' potential for carsickness research. 61
31422261 2019
Motion sickness-susceptible participants exposed to coherent rotating dot patterns show excessive N2 amplitudes and impaired theta-band phase synchronization. 61
31326576 2019
Changes in skin blood flow, respiration and blood pressure in participants reporting motion sickness during sinusoidal galvanic vestibular stimulation. 61
31468621 2019
Effectiveness of three-dimensional visualisation on undergraduate nursing and midwifery students' knowledge and achievement in pharmacology: A mixed methods study. 61
31306850 2019
Motion sickness in passenger vehicles during test track operations. 61
31282785 2019
Knowing What's Coming: Unpredictable Motion Causes More Motion Sickness. 61
31590575 2019
What Players of Virtual Reality Exercise Games Want: Thematic Analysis of Web-Based Reviews. 61
31538951 2019

Variations for Motion Sickness

Expression for Motion Sickness

Search GEO for disease gene expression data for Motion Sickness.

Pathways for Motion Sickness

Pathways related to Motion Sickness according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
4 11.71 TACR1 FOS AQP1
5 11.67 HTR3B HTR3A HTR1A
6 11.64 POMC OPRM1 FOS
Show member pathways
Show member pathways
10.53 HTR3B HTR3A
10 10.1 TACR1 TAC1

GO Terms for Motion Sickness

Cellular components related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.24 ZNF451 TACR1 PCSK5 OPRM1 IRGC HTR3B
2 synapse GO:0045202 9.73 TAC1 HTR3B HTR3A HTR1A HRH1 CNR1
3 secretory granule GO:0030141 9.5 POMC PCSK5 AVP
4 integral component of presynaptic membrane GO:0099056 9.33 OPRM1 HTR3A CNR1
5 integral component of plasma membrane GO:0005887 9.28 TACR1 OPRM1 HTR3B HTR3A HTR1A HRH1
6 serotonin-activated cation-selective channel complex GO:1904602 8.96 HTR3B HTR3A

Biological processes related to Motion Sickness according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.81 TAC1 OPRM1 FOS CNR1
2 G protein-coupled receptor signaling pathway GO:0007186 9.81 TACR1 TAC1 POMC OPRM1 HTR1A HRH1
3 chemical synaptic transmission GO:0007268 9.8 TAC1 HTR3B HTR3A HTR1A HRH1
4 glucose homeostasis GO:0042593 9.77 POMC CNR1 ADRA2A
5 neuropeptide signaling pathway GO:0007218 9.74 TAC1 POMC OPRM1
6 response to ethanol GO:0045471 9.73 OPRM1 HTR3A CNR1 AVP
7 cell-cell signaling GO:0007267 9.72 TAC1 POMC PCSK5 AVP ADRA2A
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.71 TACR1 OPRM1 HRH1
9 sensory perception of pain GO:0019233 9.7 TAC1 OPRM1 CNR1
10 signal transduction GO:0007165 9.7 TACR1 POMC OPRM1 HTR3B HTR3A HTR1A
11 response to cocaine GO:0042220 9.67 OPRM1 HTR3A CNR1
12 response to morphine GO:0043278 9.63 TAC1 OPRM1 CNR1
13 response to pain GO:0048265 9.6 TACR1 TAC1
14 vasoconstriction GO:0042310 9.58 HTR1A AVP
15 water transport GO:0006833 9.58 AVP AQP1
16 multicellular organismal water homeostasis GO:0050891 9.56 AVP AQP1
17 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 OPRM1 HTR1A HRH1 CNR1
18 tachykinin receptor signaling pathway GO:0007217 9.55 TACR1 TAC1
19 detection of abiotic stimulus GO:0009582 9.48 TACR1 TAC1
20 positive regulation of saliva secretion GO:0046878 9.37 TAC1 AQP1
21 serotonin receptor signaling pathway GO:0007210 8.8 HTR3B HTR3A HTR1A

Molecular functions related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.63 TACR1 OPRM1 HTR1A HRH1 CNR1 ADRA2A
2 serotonin binding GO:0051378 9.26 HTR3A HTR1A
3 serotonin-gated cation-selective channel activity GO:0022850 8.96 HTR3B HTR3A
4 neurotransmitter receptor activity GO:0030594 8.92 HTR3B HTR3A HTR1A HRH1

Sources for Motion Sickness

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....